期刊
NANO TODAY
卷 8, 期 4, 页码 374-387出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2013.07.001
关键词
Circulating tumor cells; Nano surface; Cancer; Diagnosis; Biomarkers; Heterogeneity
资金
- NSF [1150733]
- [U54 EB015408]
- [R21 HL112114]
- [R01 AI093282]
- [R01 AI081534]
- [R21 AI087107]
- [R21 HL095960]
- [R01 EB015776]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL095960, R21HL112114] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093282, R01AI081534, R21AI087107] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [U54EB015408, R01EB015776] Funding Source: NIH RePORTER
Circulating tumor cells (CTCs) originate from the primary tumor mass and enter into the peripheral bloodstream. CTCs hold the key to understanding the biology of metastasis and also play a vital role in cancer diagnosis, prognosis, disease monitoring, and personalized therapy. However, CTCs are rare in blood and hard to isolate. Additionally, the viability of CTCs can easily be compromised under high shear stress while releasing them from a surface. The heterogeneity of CTCs in biomarker expression makes their isolation quite challenging; the isolation efficiency and specificity of current approaches need to be improved. Nanostructured substrates have emerged as a promising biosensing platform since they provide better isolation sensitivity at the cost of specificity for CTC isolation. This review discusses major challenges faced by CTC isolation techniques and focuses on nanostructured substrates as a platform for CTC isolation. (c) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据